Roche announced that
the European Commission (EC) has
given its approval for the wider use of Avastin (bevacizumab) in patients
suffering from metastatic colorectal cancer. The new broader label will now
allow Avastin to be used in combination with any chemotherapy, including
Roche's oral chemotherapy Xeloda (capecitabine), for first and later treatment
lines in patients with metastatic colorectal cancer.